High fitness has been linked to reductions in risk of developing and dying from lung, colorectal cancer.
The biggest challenges in incorporating biomarker testing into lung cancer care occur when a tissue sample is of insufficient size or quality.
The American College of Chest Physicians now recommends offering low-dose computed tomography scanning to persons at high risk for lung cancer.
The cobas EGFR Mutation Test, a companion diagnostic for Tarceva, has been approved by the FDA to detect lung-cancer-related gene mutation.
MnDCT has similar radiation to X-ray but greater sensitivity for detecting new and recurrent cancer.
Intraventricular chemotherapy to the brain improved symptoms and survival in persons with leptomeningeal carcinomatosis following lung cancer.
Testosterone levels were below the lower limit of normal in 84% of men undergoing crizotinib therapy for the treatment of lung cancer.
A new chemotherapy regimen appears to produce minimal side effects in patients with lung cancer that has not responded to previous therapy, paving the way for additional research to determine if the new regimen also helps shrink tumors.
People with non-small cell lung cancer who become resistant to cisplatin may be able to counteract this problem with PARP inhibitors.
After a decade of biomarker testing in lung cancer, a uniform approach for testing for the EGFR mutation and ALK rearrangement along with the availability of targeted therapies offer lung cancer patients the chance for improved quality of life and more time with their loved ones.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|